cynoLAG-3-HEK293 is primarily used in immunological research and drug development, particularly in studies involving immune checkpoint pathways. It serves as a critical tool for evaluating the interaction between LAG-3 (Lymphocyte Activation Gene-3) and its ligands, which play a key role in downregulating T-cell activity. This cell-based assay system is engineered to support high-throughput screening of therapeutic agents such as monoclonal antibodies or small molecules designed to block LAG-3 signaling. It is widely employed in oncology research to assess the efficacy of immune-modulating therapies, especially in the development of cancer immunotherapies. The HEK293 expression platform ensures consistent and reliable protein expression, making it suitable for functional validation and binding affinity studies during preclinical development.